47.38
-1.46 (-2.99%)
| Penutupan Terdahulu | 48.84 |
| Jumlah Dagangan | 21,416,811 |
| Harga / Pendapatan (P/E Ke hadapan) | 23.42 |
| Harga / Jualan (P/S) | 8.01 |
| Harga / Buku (P/B) | 3.64 |
| Julat 52 Minggu |
| Margin Keuntungan | 17.97% |
| Margin Operasi (TTM) | 27.38% |
| EPS Cair (TTM) | 0.850 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 18.30% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 63.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 10.86% |
| Nisbah Semasa (MRQ) | 2.73 |
| Aliran Tunai Operasi (OCF TTM) | 5.22 B |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -2.30 B |
| Pulangan Atas Aset (ROA TTM) | 5.05% |
| Pulangan Atas Ekuiti (ROE TTM) | 8.82% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (HK) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | WUXI BIO | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 0.5 |
| Purata | -0.44 |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| WUXI BIO | - | - | - | 3.64 |
| INNOVENT BIO | - | - | - | 7.57 |
| SBP GROUP | - | 1.15% | - | 2.47 |
| AKESO | - | - | - | 8.83 |
| ASCENTAGE | - | - | - | 19.80 |
| KEYMED BIO-B | - | - | - | 5.00 |
|
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing, refining, and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Large Core |
| % Dimiliki oleh Orang Dalam | 13.07% |
| % Dimiliki oleh Institusi | 35.91% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |